We calculated the IPS of GC patients from TCGA-STAD and found that patients with low levels of CLEC11A expression presented significant therapeutic benefits from ICI treatments (CTLA4-/PD-1- and CTLA4+/PD-1-) (Figure 8D). Here, CTLA4 is linked to gastric cancer.